<div id="readability-page-1"><p>Flputnam Investment Management Co. decreased its holdings in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 65,207 shares of the company's stock after selling 9,788 shares during the period. Flputnam Investment Management Co.'s holdings in Johnson &amp; Johnson were worth $12,091,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul><p>Other large investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new stake in  Johnson &amp; Johnson in the second quarter valued at about $27,000.  Semmax Financial Advisors Inc. increased its stake in shares of  Johnson &amp; Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after acquiring an additional 72 shares during the last quarter.  GFG Capital LLC bought a new stake in shares of  Johnson &amp; Johnson in the 2nd quarter valued at about $35,000.  1248 Management LLC acquired a new stake in shares of  Johnson &amp; Johnson in the 1st quarter valued at approximately $48,000.  Finally, Vermillion &amp; White Wealth Management Group LLC boosted its stake in  Johnson &amp; Johnson by 66.4% during the 2nd quarter. Vermillion &amp; White Wealth Management Group LLC now owns 376 shares of the company's stock worth $57,000 after acquiring an additional 150 shares during the last quarter. Institutional investors and hedge funds own  69.55% of the company's stock. </p><h2>Johnson &amp; Johnson Price Performance</h2><p>JNJ stock opened at $206.49 on Monday. The stock has a 50-day moving average price of $198.10 and a two-hundred day moving average price of $179.38. Johnson &amp; Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The stock has a market cap of $497.49 billion, a PE ratio of 19.93, a price-to-earnings-growth ratio of 2.24 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. </p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter.  Equities analysts forecast that  Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 50.19%. </p><h2>Johnson &amp; Johnson News Summary</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Here are the key news stories impacting Johnson &amp; Johnson this week:</p><ul>   <li><span>Positive Sentiment: </span>FDA approves a subcutaneous version of Rybrevant (amivantamab) that reduces administration time from hours to minutes for EGFR‑mutated NSCLC — this materially improves patient convenience, may raise uptake vs. IV therapy and supports long‑term revenue potential for JNJ’s lung‑cancer franchise. <i></i><span>J&amp;J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant</span></li>    <li><span>Positive Sentiment: </span>FDA clears RYBREVANT FASPRO (amivantamab + hyaluronidase) as the first subcutaneous therapy across Rybrevant indications, enabling much shorter, simpler first‑line regimens when combined with LAZCLUZE — a regulatory win that supports commercial uptake and margins. <i></i><span>U.S. FDA Approval of RYBREVANT FASPRO</span></li>    <li><span>Positive Sentiment: </span>JNJ’s MedTech unit won FDA clearance for the TRUFILL n‑BCA liquid embolic system to treat symptomatic chronic subdural hematoma (cSDH), expanding neurovascular indications and supporting device revenue growth. <i></i><span>Johnson &amp; Johnson Receives FDA Approval for TRUFILL n‑BCA</span></li>    <li><span>Positive Sentiment: </span>Media and investor sentiment is bullish: Jim Cramer highlighted JNJ’s oncology momentum and broader rotation into healthcare/defensive names, which can drive retail interest and support multiple expansion. <i></i><span>Jim Cramer Couldn’t Stop Gushing About Johnson &amp; Johnson (JNJ)’s Cancer Drugs</span></li>    <li><span>Neutral Sentiment: </span>Analyst/valuation commentary argues JNJ’s premium multiple is supported by accelerating growth and portfolio mix; useful context for longer‑term positioning but less likely to move near‑term price. <i></i><span>Johnson and Johnson: Valuation Premium Justified By Accelerating Growth</span></li>    <li><span>Neutral Sentiment: </span>Macro note: rate cuts and dividend‑friendly ETF flows (e.g., mentions in MarketBeat pieces) can support demand for high‑quality dividend payers like JNJ, but impact is gradual. <i></i><span>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</span></li>    <li><span>Negative Sentiment: </span>Near‑term pullback likely driven by profit‑taking after a large YTD move (shares are up significantly year‑to‑date); heavy volume suggests short‑term selling pressure despite positive catalysts. </li> </ul><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have commented on JNJ shares. HSBC  reaffirmed a &#34;buy&#34; rating and issued a $240.00 target price on shares of Johnson &amp; Johnson in a research note on Wednesday, December 10th. Scotiabank assumed coverage on shares of Johnson &amp; Johnson in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 price objective for the company. The Goldman Sachs Group lifted their target price on Johnson &amp; Johnson from $213.00 to $240.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Loop Capital  set a $190.00 price target on Johnson &amp; Johnson in a report on Wednesday, October 22nd. Finally, Daiwa Capital Markets raised Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price target on the stock in a research report on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued  a Hold rating to the company. According to MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $210.25.</p><p><b>Check Out Our Latest Analysis on Johnson &amp; Johnson</b></p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.  </p><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>I Shouldn't Be Sending You This</li><li>REVEALED: America just unlocked a $500 trillion asset</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>They Laughed at $30. They Won’t Laugh at $70.</li><li>How Long Will $1M Last in Retirement?</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Flputnam Investment Management Co. reduced its stake in Johnson & Johnson by 13.1% in Q3, selling 9,788 shares. The fund now holds 65,207 shares valued at $12,091,000. JNJ stock opened at $206.49, with a market cap of $497.49 billion. Institutional investors own 69.55% of JNJ stock. Recent FDA approvals for JNJ's products may boost revenue and investor sentiment.</p>

Flputnam Investment Management Co. Sells 9,788 Shares of Johnson & Johnson $JNJ